Table 3 Treatment-related adverse events (n = 22)
n (%) | All grade | Grade 3/4 |
|---|---|---|
Hematologic adverse events | ||
Leukopenia | 19 (86.4) | 6 (27.3) |
Neutropenia | 20 (90.9) | 7 (31.8) |
Anemia | 22 (100.0) | 1 (4.5) |
Thrombocytopenia | 5 (22.7) | 0 (0) |
Febrile neutropenia | 1 (4.5) | 1 (4.5) |
Nonhematologic adverse events (≥ 10%) | ||
Nausea | 18 (81.8) | 0 (0) |
Vomiting | 4 (18.2) | 0 (0) |
Constipation | 19 (86.4) | 0 (0) |
Diarrhea | 5 (22.7) | 0 (0) |
Stomatitis | 5 (22.7) | 0 (0) |
Anorexia | 20 (90.9) | 1 (4.5) |
Fatigue | 15 (68.2) | 1 (4.5) |
Pain | 6 (27.3) | 0 (0) |
Fever | 3 (13.6) | 0 (0) |
Weight loss | 3 (13.6) | 0 (0) |
Alopecia | 15 (68.2) | 0 (0) |
Rash | 6 (27.3) | 0 (0) |
AST increase | 4 (18.2) | 0 (0) |
ALT increase | 9 (40.9) | 0 (0) |
ALP increase | 11 (50.0) | 0 (0) |
Blood bilirubin increase | 4 (18.2) | 0 (0) |
Creatinine increase | 7 (31.8) | 0 (0) |
Hypoalbuminemia | 18 (81.8) | 0 (0) |
Hyperkalemia | 15 (68.2) | 1 (4.5) |
Hypocalcemia | 4 (18.2) | 0 (0) |
Hypokalemia | 5 (22.7) | 0 (0) |
Hyponatremia | 5 (22.7) | 4 (18.2) |
Peripheral sensory neuropathy | 6 (27.3) | 1 (4.5) |
Myalgia | 3 (13.6) | 0 (0) |
Lung infection | 4 (18.2) | 4 (18.2) |